Yonsei University · Medicine
Professor Yong-Joon Lee's research lab specializes in clinical and translational research, with a strong focus on regenerative medicine, tissue engineering, and stem cell therapy. The lab conducts rigorous clinical trials—such as those registered on ClinicalTrials.gov (e.g., NCT03044665, NCT02579499)—to evaluate the safety and efficacy of stem cell-based interventions in conditions like spinal cord injury and degenerative diseases. The lab also engages in systematic reviews and prospective studies (e.g., PROSPERO CRD42024532550), emphasizing evidence-based approaches in regenerative therapies. Their work bridges preclinical findings with human applications, aiming to advance personalized and cell-based treatments.
Figures are computed from collected data and may differ slightly.
ClinicalTrials.gov, Identifier:NCT03044665.
ClinicalTrials.gov NCT02579499.
[Figure: see text].
ClinicalTrials.gov Identifier: NCT02494895.
gov: NCT02513810.
PROSPERO CRD42024532550.
PROSPERO (ID: CRD42023476470).
[www.ClinicalTrials.gov], identifier [NCT03298282].
In patients with MetS and atherosclerotic cardiovascular disease, a moderate-intensity statin with ezetimibe combination therapy had comparable cardiovascular benefits with those of high-intensity statin monotherapy. Meanwhile, ezetimibe combination therapy was associated with lower drug intolerance and low-density lipoprotein cholesterol levels, but there was no apparent between-group difference in new-onset diabetes.
Open papers in the app to read, cite, and organize with AI.
